CTOs on the Move

FerGene

www.fergene.com

 
FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.fergene.com
  • 245 Main Street
    Cambridge, MA USA 02142
  • Phone: 617.865.5780

Executives

Name Title Contact Details

Similar Companies

TandemAI

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.

ARIAD Pharmaceuticals, Inc.

ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets. 

Industrial Biotechnology Corporation

Industrial Biotechnology Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Morphosys USA

Morphosys USA, Inc. is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.